| 臺大學術典藏 |
2022-01-24T09:32:00Z |
Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection
|
Hsu C.-S.; Liu C.-H.; CHUN-JEN LIU; Hsu S.-J.; Chen C.-L.; Hwang J.-J.; Lai M.-Y.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:32:00Z |
The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Hsu S.-J.; Lin J.-W.; Chen S.-I.; Hung P.-H.; Tsai H.-B.; Lai M.-Y.; Chen P.-J.; Chen J.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:56Z |
HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection
|
Hsu S.-J.; Hsu C.-S.; Liu C.-H.; CHUN-JEN LIU; Chen C.-L.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:55Z |
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
|
Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Tseng T.-C.; Liu C.-H.; Niu W.-F.; Jeng J.; CHUN-JEN LIU; Lai M.-Y.; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:51Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:49Z |
IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients
|
Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen C.-L.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:47Z |
Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients
|
Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Liu C.-H.; Jeng J.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:33Z |
Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients
|
Yang C.-C.; Tsai W.-L.; Su W.-W.; Huang C.-F.; Cheng P.-N.; Lo C.-C.; Tseng K.-C.; Mo L.-R.; Wang C.-H.; Hsu S.-J.; Lai H.-C.; Su C.-W.; CHUN-JEN LIU; Peng C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:23Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; CHUN-JEN LIU; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; CHUN-JEN LIU; Kao J.-H.; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; Hsu S.-J.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:52Z |
Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan
|
Hong C.-M.; Lin Y.-Y.; CHUN-JEN LIU; Lai Y.-Y.; Yeh S.-H.; Yang H.-C.; Kao J.-H.; Hsu S.-J.; Huang Y.-H.; Yang S.-S.; Kuo H.-T.; Cheng P.-N.; Yu M.-L.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-13T08:46:00Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; PO-JEN YANG; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; Yang W.-S. |
| 國立成功大學 |
2022 |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang, C.-F.;Tseng, K.-C.;Cheng, P.-N.;Hung, C.-H.;Lo, C.-C.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Chen, Chen C.-H.;Lee, P.-L.;Lin, C.-Y.;Kuo, H.-T.;Chen, Chen C.-T.;Yang, C.-C.;Huang, J.-F.;Tai, C.-M.;Hu, J.-T.;Lin, C.-L.;Su, W.-W.;Tsai, W.-L.;Huang, Y.-H.;Cheng, Cheng C.-Y.;Lin, C.-L.;Wang, C.-C.;Yang, S.-S.;Mo, L.-R.;Chen, G.-Y.;Chang, Chang C.-C.;Wang, S.-J.;Huang, C.-S.;Hsieh, T.-Y.;Lin, C.-W.;Lee, T.-H.;Chong, L.-W.;Huang, C.-W.;Chang, S.-N.;Tsai, M.-C.;Hsu, S.-J.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Lin, H.-C.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Chuang, W.-L.;Chen, Chen C.-Y.;Yu, M.-L. |
| 臺大學術典藏 |
2021-09-04T06:12:35Z |
Esophageal varices: Noninvasive diagnosis with duplex doppler US in patients with compensated cirrhosis
|
Liu C.-H.; Hsu S.-J.; Liang C.-C.; Tsai F.-C.; Lin J.-W.; Liu C.-J.; Yang P.-M.; Lai M.-Y.; Chen P.-J.; Chen J.-H.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:31Z |
Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
|
Liu C.-H.; Liu C.-J.; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:27Z |
Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tsai H.-B.; Hung P.-H.; Hsu S.-J.; Chen S.-L.; Lin J.-W.; Lai M.-Y.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:22Z |
Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection
|
Hsu C.-S.; Liu C.-H.; Liu C.-J.; Hsu S.-J.; Chen C.-L.; Hwang J.-J.; Lai M.-Y.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:21Z |
The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Hsu S.-J.; Lin J.-W.; Chen S.-I.; Hung P.-H.; Tsai H.-B.; Lai M.-Y.; Chen P.-J.; Chen J.-H.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:10Z |
HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection
|
Hsu S.-J.; Hsu C.-S.; Liu C.-H.; Liu C.-J.; Chen C.-L.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:08Z |
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
|
Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Tseng T.-C.; Liu C.-H.; Niu W.-F.; Jeng J.; Liu C.-J.; Lai M.-Y.; Chen P.-J.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:53Z |
IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients
|
Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen C.-L.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:50Z |
Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients
|
Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Liu C.-H.; Jeng J.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:38Z |
A pilot study of add-on oral hypoglycemic agents in treatment-na?ve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
|
Hsu C.-S.; Hsu S.-J.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:13Z |
Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy
|
Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-09-04T06:11:06Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S. |
| 臺大學術典藏 |
2021-09-04T06:10:54Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; JIA-HORNG KAO; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; JIA-HORNG KAO; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-09-04T05:16:55Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T05:16:49Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:44Z |
Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?
|
Hsu S.-J.; Yang S.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:42Z |
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
|
Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO; Hsu S.-J.; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T05:16:40Z |
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
|
Hsu S.-J.; Enkhzaya S.; Lin Y.-Y.; Tseng T.-C.; Khosbayar T.; Tsai C.-H.; Wang T.-S.; Enkhtuya D.; Ivshinkhorol D.; Naranzul N.; Jargalsaikhan B.; Amarsanaa J.; Baatarkhuu O.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:21Z |
Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy
|
Su T.-H.; Hsu S.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-07-03T03:35:34Z |
Induction of humoral and cellular immune responses to hepatitis delta virus through DNA immunization in BALB/c mice.
|
Lee R.S.; Hsu S.J.; Huang L.R.; Wu H.L.; Lin S.L.; Chen D.S.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:35:23Z |
Trichuris suis therapy for ulcerative colitis: Nonresponsive patients may need anti-helminth therapy [2] (multiple letters)
|
Hsu S.-J.; Tseng P.-H.; PEI-JER CHEN; Summers R.W.; Elliott D.E.; Weinstock J.V. |
| 臺大學術典藏 |
2021-07-03T03:35:05Z |
Esophageal varices: Noninvasive diagnosis with duplex doppler US in patients with compensated cirrhosis
|
Liu C.-H.; Hsu S.-J.; Liang C.-C.; Tsai F.-C.; Lin J.-W.; Liu C.-J.; Yang P.-M.; Lai M.-Y.; PEI-JER CHEN; Chen J.-H.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:58Z |
Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
|
Liu C.-H.; Liu C.-J.; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:54Z |
Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tsai H.-B.; Hung P.-H.; Hsu S.-J.; Chen S.-L.; Lin J.-W.; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:49Z |
Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection
|
Hsu C.-S.; Liu C.-H.; Liu C.-J.; Hsu S.-J.; Chen C.-L.; Hwang J.-J.; Lai M.-Y.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:48Z |
The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Hsu S.-J.; Lin J.-W.; Chen S.-I.; Hung P.-H.; Tsai H.-B.; Lai M.-Y.; PEI-JER CHEN; Chen J.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:36Z |
HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection
|
Hsu S.-J.; Hsu C.-S.; Liu C.-H.; Liu C.-J.; Chen C.-L.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:35Z |
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
|
Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Tseng T.-C.; Liu C.-H.; Niu W.-F.; Jeng J.; Liu C.-J.; Lai M.-Y.; PEI-JER CHEN; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:27Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:24Z |
IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients
|
Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen C.-L.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:16Z |
Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients
|
Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Liu C.-H.; Jeng J.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:34Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.;Hung C.-H.;Huang Y.-H.;Peng C.-Y.;Lin C.-Y.;Cheng P.-N.;Chien R.-N.;Hsu S.-J.;Liu C.-H.;Huang C.-F.;Su C.-W.;Huang J.-F.;Liu C.-J.;Kao J.-H.;Chuang W.-L.;Pei-Jer Chen;Chen D.-S.; Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; Kao J.-H.; Chuang W.-L.; PEI-JER CHEN; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:33:19Z |
Ropeginterferon alfa-2b every 2?weeks as a novel pegylated interferon for patients with chronic hepatitis B
|
Huang Y.-W.; Hsu C.-W.; Lu S.-N.; Yu M.-L.; Su C.-W.; Su W.-W.; Chien R.-N.; Hsu C.-S.; Hsu S.-J.; Lai H.-C.; Qin A.; Tseng K.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-02T02:35:20Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; WEI-SHIUNG YANG |
